
Youngchul Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3499986/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Randomized Clinical Trial of Precision Prevention Materials Incorporating <i>MC1R</i> Genetic Risk to Improve Skin Cancer Prevention Activities Among Hispanics. Cancer Research Communications, 2022, 2, 28-38.	1.7	9
2	Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma. Cancer Research, 2022, 82, 929-942.	0.9	13
3	Assessment of melanoma precision prevention materials incorporating <i>MC1R</i> genetic risk information. Translational Behavioral Medicine, 2022, 12, 683-687.	2.4	3
4	Retention and Evaluation of Precision and Generic Prevention Materials for Melanoma: A Qualitative Study Comparing Young Adults and Adults. Cancer Prevention Research, 2022, 15, 533-542.	1.5	1
5	Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma. European Urology, 2022, 82, 354-362.	1.9	13
6	Assessment of skin cancer precision prevention materials among Hispanics in Florida and Puerto Rico. Patient Education and Counseling, 2022, 105, 3143-3150.	2.2	1
7	Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy. European Urology Focus, 2021, 7, 373-380.	3.1	4
8	PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients. BMC Bioinformatics, 2020, 21, 288.	2.6	13
9	Investigating multi-radiomic models for enhancing prediction power of cervical cancer treatment outcomes. Physica Medica, 2018, 46, 180-188.	0.7	34
10	Impact of viral presence in tumor on gene expression in non-small cell lung cancer. BMC Cancer, 2018, 18, 843.	2.6	16
11	CONCORD biomarker prediction for novel drug introduction to different cancer types. Oncotarget, 2018, 9, 1091-1106.	1.8	5
12	Point success rate for patient therapeutic response prediction by continuous biomarker scores. Statistical Methods in Medical Research, 2016, 25, 1638-1647.	1.5	0
13	Retrospective Analysis of Survival Improvement by Molecular Biomarker-Based Personalized Chemotherapy for Recurrent Ovarian Cancer. PLoS ONE, 2014, 9, e86532.	2.5	13
14	Multi-Gene Expression Predictors of Single Drug Responses to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance. PLoS ONE, 2012, 7, e30550.	2.5	95
15	A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients to Chemotherapy. PLoS ONE, 2012, 7, e49529.	2.5	20
16	Double error shrinkage method for identifying protein binding sites observed by tiling arrays with limited replication. Bioinformatics, 2009, 25, 2486-2491.	4.1	1